Update on estrogens and the skeleton.

CONTEXT The very clinical trial, the Women's Health Initiative, which definitely established the antifracture efficacy of estrogen therapy, led to the demise of estrogen treatment as a viable, long-term option for prevention of bone loss in postmenopausal women due to the well-publicized adverse effects of estrogen plus progestin therapy on a number of nonskeletal endpoints. Given the diminishing clinical use of estrogen, it is logical to question whether estrogen regulation of bone remains a relevant issue at a clinical or basic research level. EVIDENCE ACQUISITION Findings of this update are based on a PubMed search and the author's knowledge of the field. EVIDENCE SYNTHESIS Basic and clinical studies on the mechanisms of estrogen effects on bone will continue to provide potential novel drug targets for the prevention and treatment of osteoporosis. At a clinical level, it is clear that even the low levels of estrogen present in postmenopausal women have a significant impact on bone turnover, leading to a more aggressive approach to prevent bone loss in patients with breast cancer on aromatase inhibitors. Conversely, increasing these low estrogen levels with small doses of estrogen may have beneficial skeletal effects in postmenopausal women without adverse effects on reproductive tissues. Finally, the search continues for new selective estrogen receptor modulators with beneficial effects on bone and other tissues. CONCLUSIONS Even in the post-WHI era, basic and clinical investigation on estrogen and bone will continue to yield important insights that not only expand our knowledge at a basic level but also impact the health of our aging population.

[1]  A. Díez-Pérez,et al.  Anti-vertebral fracture efficacy of raloxifene: a meta-analysis , 2006, Osteoporosis International.

[2]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Lane,et al.  Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen , 1992, Annals of Internal Medicine.

[4]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[5]  S. Khosla Increasing options for the treatment of osteoporosis. , 2009, New England Journal of Medicine.

[6]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[7]  N. Watts,et al.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy , 2008, Osteoporosis International.

[8]  S. Manolagas,et al.  Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. , 2000, Endocrine reviews.

[9]  D. Lacey,et al.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.

[10]  Roberto Pacifici,et al.  Estrogen deficiency and bone loss: an inflammatory tale. , 2006, The Journal of clinical investigation.

[11]  D. McDonnell Mining the complexities of the estrogen signaling pathways for novel therapeutics. , 2003, Endocrinology.

[12]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[13]  R. Jilka Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. , 2007, Bone.

[14]  F. Collins,et al.  The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. , 2007, Bone.

[15]  Li Han,et al.  Transient Versus Sustained Phosphorylation and Nuclear Accumulation of ERKs Underlie Anti-Versus Pro-apoptotic Effects of Estrogens* , 2005, Journal of Biological Chemistry.

[16]  J. Reeve,et al.  The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. , 1997, The Journal of clinical endocrinology and metabolism.

[17]  S. Cummings,et al.  Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.

[18]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[19]  P. Chambon,et al.  Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts , 2007, Cell.

[20]  B. L. Riggs,et al.  Effect of Blockade of TNF‐α and Interleukin‐1 Action on Bone Resorption in Early Postmenopausal Women , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  J. Krege,et al.  Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. , 2009, The Journal of clinical endocrinology and metabolism.

[22]  R. Lindsay,et al.  Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. , 2009, Fertility and sterility.

[23]  R. Marcus Post-menopausal osteoporosis. , 2002, Best practice & research. Clinical obstetrics & gynaecology.

[24]  B. Whitcomb,et al.  Long-term impact of the women’s health initiative on HRT , 2008, Archives of Gynecology and Obstetrics.

[25]  L. Melton,et al.  Role of Low Levels of Endogenous Estrogen in Regulation of Bone Resorption in Late Postmenopausal Women , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  R. Eastell,et al.  Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. , 2000, The Journal of clinical investigation.

[27]  A. LaCroix,et al.  Lasofoxifene in postmenopausal women with osteoporosis. , 2010, The New England journal of medicine.

[28]  S. Khosla Estrogen and the death of osteoclasts: A fascinating story , 2007 .

[29]  S. Cawthorn,et al.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.

[30]  C. Roux,et al.  Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer. , 2009, Best practice & research. Clinical rheumatology.

[31]  E. Perez,et al.  Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Elevated parathyroid hormone-related peptide associated with lactation and bone density loss , 1996 .

[33]  J. Forbes,et al.  Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. King,et al.  A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. , 1998, The American journal of clinical nutrition.

[35]  P. Roberson,et al.  Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. , 1998, The Journal of clinical investigation.

[36]  S. Khosla Update in male osteoporosis. , 2010, The Journal of clinical endocrinology and metabolism.

[37]  Sundeep Khosla,et al.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. , 2008, Endocrine reviews.

[38]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[39]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[40]  J. Wysolmerski,et al.  Low estrogen and high parathyroid hormone-related peptide levels contribute to accelerated bone resorption and bone loss in lactating mice. , 2003, Endocrinology.

[41]  Jennifer J Westendorf,et al.  Building bone to reverse osteoporosis and repair fractures. , 2008, The Journal of clinical investigation.

[42]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[43]  S. Cummings,et al.  Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial , 2004, Obstetrics and gynecology.

[44]  P. Chambon,et al.  The transactivating function 1 of estrogen receptor α is dispensable for the vasculoprotective actions of 17β-estradiol , 2009, Proceedings of the National Academy of Sciences.

[45]  Mary Jane Geiger,et al.  Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women , 2006 .

[46]  Sundeep Khosla,et al.  Sex steroids and the construction and conservation of the adult skeleton. , 2002, Endocrine reviews.

[47]  P. Lønning,et al.  Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Reis,et al.  Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial , 2006 .

[49]  D. Reid Prevention of osteoporosis after breast cancer. , 2009, Maturitas.

[50]  M. Kulldorff,et al.  Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. , 2003, JAMA.

[51]  M. Beckmann,et al.  Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  C. Rosen,et al.  Developing drugs to treat osteoporosis: lessons learned? , 2010, Expert opinion on pharmacotherapy.

[53]  M. Almeida,et al.  The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. , 2010, Molecular endocrinology.

[54]  G. Constantine,et al.  Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. , 2009, Fertility and sterility.